{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:35:21Z","timestamp":1787225721688,"version":"build-2736575974"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T00:00:00Z","timestamp":1554768000000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.lungcan.2019.02.017","type":"journal-article","created":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T16:30:54Z","timestamp":1550593854000},"page":"194-200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Potential for the blood-based biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 4 (HE4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung"],"prefix":"10.1016","volume":"130","author":[{"given":"Thomas","family":"Muley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinzent","family":"Rolny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Wehnl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Escherich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Warth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa","family":"Stolp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7534-5431","authenticated-orcid":false,"given":"Marc A.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Meister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix J.","family":"Herth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farshid","family":"Dayyani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2019.02.017_bib0005","series-title":"Surveillance, Epidemiology, and End Results Program (SEER) Stat Fact Sheets: Lung and Bronchus Cancer","year":"2016"},{"key":"10.1016\/j.lungcan.2019.02.017_bib0010","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","article-title":"Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship","volume":"83","author":"Molina","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.lungcan.2019.02.017_bib0015","doi-asserted-by":"crossref","DOI":"10.1378\/chest.12-2359","article-title":"Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"143","author":"Howington","year":"2013","journal-title":"Chest"},{"issue":"Suppl 5","key":"10.1016\/j.lungcan.2019.02.017_bib0020","doi-asserted-by":"crossref","first-page":"v103","DOI":"10.1093\/annonc\/mdq207","article-title":"Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Crino","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2019.02.017_bib0025","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1200\/JCO.2005.04.4859","article-title":"Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database","volume":"24","author":"Govindan","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2019.02.017_bib0030","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1056\/NEJMoa043623","article-title":"Vinorelbine plus cisplatin vs. Observation in resected non-small-cell lung cancer","volume":"352","author":"Winton","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2019.02.017_bib0035","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa031644","article-title":"Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer","volume":"350","author":"Arriagada","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2019.02.017_bib0040","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jtcvs.2012.09.030","article-title":"Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance","volume":"145","author":"Lou","year":"2013","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.lungcan.2019.02.017_bib0045","doi-asserted-by":"crossref","DOI":"10.1378\/chest.12-2365","article-title":"Follow-up and surveillance of the patient with lung cancer after curative-intent therapy: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"143","author":"Colt","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.lungcan.2019.02.017_bib0050","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1097\/JTO.0b013e31822b01a1","article-title":"Survival benefits from follow-up of patients with lung cancer: a systematic review and meta-analysis","volume":"6","author":"Calman","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2019.02.017_bib0055","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/annonc\/mdu089","article-title":"2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up","volume":"25","author":"Vansteenkiste","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2019.02.017_bib0060","first-page":"408","article-title":"PET\/CT vs. Non-contrast CT alone for surveillance 1-year post lobectomy for stage I non-small-cell lung cancer","volume":"3","author":"Dane","year":"2013","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.lungcan.2019.02.017_bib0065","series-title":"Non-small Cell Lung Cancer; Version 4.2016","author":"National Comprehensive Cancer network (NCCN)","year":"2015"},{"key":"10.1016\/j.lungcan.2019.02.017_bib0070","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jtcvs.2013.08.060","article-title":"Minimal-dose computed tomography is superior to chest x-ray for the follow-up and treatment of patients with resected lung cancer","volume":"147","author":"Hanna","year":"2014","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.lungcan.2019.02.017_bib0075","first-page":"1605","article-title":"The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification","volume":"42","author":"Hicks","year":"2001","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.lungcan.2019.02.017_bib0080","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.thorsurg.2014.12.005","article-title":"Current estimate of costs of lung cancer screening in the United States","volume":"25","author":"Mauchley","year":"2015","journal-title":"Thorac. Surg. Clin."},{"key":"10.1016\/j.lungcan.2019.02.017_bib0085","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.lungcan.2013.12.005","article-title":"Healthcare costs in the Danish randomised controlled lung cancer CT-screening trial: a registry study","volume":"83","author":"Rasmussen","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2019.02.017_bib0090","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/ijcp.12744","article-title":"Lung cancer screening: a systematic review of clinical practice guidelines","volume":"70","author":"Li","year":"2016","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.lungcan.2019.02.017_bib0095","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3322\/caac.21239","article-title":"Issues with implementing a high-quality lung cancer screening program","volume":"64","author":"Mulshine","year":"2014","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lungcan.2019.02.017_bib0100","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1378\/chest.13-1420","article-title":"Radiation risks in lung cancer screening programs","volume":"145","author":"McCunney","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.lungcan.2019.02.017_bib0105","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1159\/000317580","article-title":"The value of tumor markers in evaluating chemotherapy response and prognosis in Chinese patients with advanced non-small cell lung cancer","volume":"56","author":"Jin","year":"2010","journal-title":"Chemotherapy"},{"key":"10.1016\/j.lungcan.2019.02.017_bib0110","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1177\/172460080401900409","article-title":"Early CYFRA 21-1 variation predicts tumor response to chemotherapy and survival in locally advanced non-small cell lung cancer patients","volume":"19","author":"Merle","year":"2004","journal-title":"Int. J. Biol. Markers"},{"key":"10.1016\/j.lungcan.2019.02.017_bib0115","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000074432","article-title":"Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors","volume":"24","author":"Molina","year":"2003","journal-title":"Tumour Biol."},{"key":"10.1016\/j.lungcan.2019.02.017_bib0120","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1038\/sj.bjc.6601851","article-title":"CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients","volume":"90","author":"Pujol","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2019.02.017_bib0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128836","article-title":"Serum HE4: an independent prognostic factor in non-small cell lung Cancer","volume":"10","author":"Lamy","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2019.02.017_bib0130","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s13277-012-0356-9","article-title":"Serum HE4 as a diagnostic and prognostic marker for lung cancer","volume":"33","author":"Iwahori","year":"2012","journal-title":"Tumour Biol."},{"key":"10.1016\/j.lungcan.2019.02.017_bib0135","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s12094-015-1375-y","article-title":"Serum human epididymis protein 4 is associated with the treatment response of concurrent chemoradiotherapy and prognosis in patients with locally advanced non-small cell lung cancer","volume":"18","author":"Lan","year":"2016","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.lungcan.2019.02.017_bib0140","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/sj.bjc.6604157","article-title":"Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival","volume":"98","author":"Nisman","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2019.02.017_bib0145","first-page":"1728","article-title":"Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response","volume":"9","author":"Vollmer","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2019.02.017_bib0150","doi-asserted-by":"crossref","first-page":"9444","DOI":"10.1038\/srep09444","article-title":"Prognostic value of serum cytokeratin 19 fragments (Cyfra 21-1) in patients with non-small cell lung cancer","volume":"5","author":"Xu","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lungcan.2019.02.017_bib0155","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/1471-2407-13-354","article-title":"Prognostic impact of serum CYFRA 21-1 in patients with advanced lung adenocarcinoma: a retrospective study","volume":"13","author":"Ono","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lungcan.2019.02.017_bib0160","first-page":"61","article-title":"Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer","volume":"53","author":"Pujol","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2019.02.017_bib0165","first-page":"1011","article-title":"CYFRA 21-1 as a tool for distant metastasis detection in lung cancer","volume":"57","author":"Cabrera-Alarcon","year":"2011","journal-title":"Clin. Lab."},{"key":"10.1016\/j.lungcan.2019.02.017_bib0170","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.5588\/ijtld.13.0058","article-title":"Evaluating the clinical significance of serum HE4 levels in lung cancer and pulmonary tuberculosis","volume":"17","author":"Liu","year":"2013","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.lungcan.2019.02.017_bib0175","first-page":"5568","article-title":"Expression level of serum human epididymis 4 and its prognostic significance in human non-small cell lung cancer","volume":"7","author":"Jiang","year":"2014","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.lungcan.2019.02.017_bib0180","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.ejcts.2007.06.032","article-title":"Preoperative CYFRA 21-1 levels as a prognostic factor in c-stage I non-small cell lung cancer","volume":"32","author":"Suzuki","year":"2007","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"10.1016\/j.lungcan.2019.02.017_bib0185","first-page":"3099","article-title":"Prognostic significance of tumour marker index based on preoperative CEA and CYFRA 21-1 in non-small cell lung cancer","volume":"30","author":"Tomita","year":"2010","journal-title":"Anticancer Res."},{"key":"10.1016\/j.lungcan.2019.02.017_bib0190","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.lungcan.2007.07.002","article-title":"Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer","volume":"58","author":"Mizuguchi","year":"2007","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2019.02.017_bib0195","first-page":"4085","article-title":"Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage I NSCLC","volume":"23","author":"Muley","year":"2003","journal-title":"Anticancer Res."},{"key":"10.1016\/j.lungcan.2019.02.017_bib0200","first-page":"501","article-title":"CYFRA 21-1 determination in patients with non-small cell lung cancer: clinical utility for the detection of recurrences","volume":"36","author":"Niklinski","year":"1995","journal-title":"J. Cardiovasc. Surg. (Torino)"},{"key":"10.1016\/j.lungcan.2019.02.017_bib0205","first-page":"2665","article-title":"CYFRA 21-1 in the early diagnosis of recurrent disease in non small cell lung carcinomas (NSCLC)","volume":"19","author":"Stieber","year":"1999","journal-title":"Anticancer Res."},{"key":"10.1016\/j.lungcan.2019.02.017_bib0210","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1007\/s13277-012-0499-8","article-title":"Serum level of HE4 is closely associated with pulmonary adenocarcinoma progression","volume":"33","author":"Yamashita","year":"2012","journal-title":"Tumour Biol."},{"key":"10.1016\/j.lungcan.2019.02.017_bib0215","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/00000421-200006000-00006","article-title":"Cytokeratin fragment 19 and squamous cell carcinoma antigen for early prediction of recurrence of squamous cell lung carcinoma","volume":"23","author":"Sun","year":"2000","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2019.02.017_bib0220","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/PL00007651","article-title":"Cytokeratin fragment 19 (CYFRA 21-1) and carcinoembryonic antigen for early prediction of recurrence of lung adenocarcinoma","volume":"177","author":"Kao","year":"1999","journal-title":"Lung"},{"key":"10.1016\/j.lungcan.2019.02.017_bib0225","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s004080000101","article-title":"Monitoring cytokeratin fragment 19 (CYFRA 21-1) serum levels for early prediction of recurrence of adenocarcinoma and squamous cell carcinoma in the lung after surgical resection","volume":"180","author":"Yeh","year":"2002","journal-title":"Lung"},{"key":"10.1016\/j.lungcan.2019.02.017_bib0230","series-title":"TNM Classification of Malignant Tumours","author":"Sobin","year":"2002"},{"key":"10.1016\/j.lungcan.2019.02.017_bib0235","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/clinchem\/39.4.561","article-title":"Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine","volume":"39","author":"Zweig","year":"1993","journal-title":"Clin. Chem."},{"key":"10.1016\/j.lungcan.2019.02.017_bib0240","series-title":"The Statistical Evaluation of Medical Tests for Classification and Prediction","author":"Pepe","year":"2004"},{"key":"10.1016\/j.lungcan.2019.02.017_bib0245","doi-asserted-by":"crossref","first-page":"370","DOI":"10.2307\/2344614","article-title":"Generalized linear models","volume":"135","author":"Nelder","year":"2004","journal-title":"J. R. Statis. Soc. Series A (General)"},{"key":"10.1016\/j.lungcan.2019.02.017_bib0250","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.athoracsur.2005.09.020","article-title":"Predicting postrecurrence survival among completely resected nonsmall-cell lung cancer patients","volume":"81","author":"Williams","year":"2006","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.lungcan.2019.02.017_bib0255","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/JTO.0b013e31821038c0","article-title":"How well does the new lung cancer staging system predict for local\/regional recurrence after surgery? A comparison of the TNM 6 and 7 systems","volume":"6","author":"Pepek","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2019.02.017_bib0260","first-page":"319","article-title":"Surgical treatment of metachronous nonsmall cell lung cancer","volume":"16","author":"Haraguchi","year":"2010","journal-title":"Ann. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.lungcan.2019.02.017_bib0265","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jtcvs.2012.05.060","article-title":"The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups","volume":"144","author":"Jaklitsch","year":"2012","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"45-52","key":"10.1016\/j.lungcan.2019.02.017_bib0270","first-page":"53","article-title":"Does the method of radiologic surveillance affect survival after resection of stage I non-small cell lung cancer?","volume":"149","author":"Crabtree","year":"2015","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.lungcan.2019.02.017_bib0275","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx378.012","article-title":"1273O Results of the phase III IFCT-0302 trial assessing minimal versus CT-scan-based follow-up for completely resected non-small cell lung cancer (NSCLC)","volume":"28","author":"Westeel","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2019.02.017_bib0280","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/annonc\/mdu089","article-title":"2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up","volume":"25","author":"Vansteenkiste","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2019.02.017_bib0285","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1148\/rg.336125105","article-title":"Identifying and distinguishing treatment effects and complications from malignancy at FDG PET\/CT","volume":"33","author":"Ulaner","year":"2013","journal-title":"Radiographics"},{"key":"10.1016\/j.lungcan.2019.02.017_bib0290","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000089260","article-title":"Tumor markers in breast cancer- European Group on Tumor Markers recommendations","volume":"26","author":"Molina","year":"2005","journal-title":"Tumour Biol."},{"key":"10.1016\/j.lungcan.2019.02.017_bib0295","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JOP.2015.009241","article-title":"In response to \"Serum tumor marker use in patients with advanced solid tumors\"","volume":"12","author":"Dayyani","year":"2016","journal-title":"J. Oncol. Pract."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500219303332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500219303332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T04:10:30Z","timestamp":1606536630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500219303332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":59,"alternative-id":["S0169500219303332"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2019.02.017","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential for the blood-based biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 4 (HE4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2019.02.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}